Prostate cancer is comprised nearly always of adenocarcinomacells -- cells that arise from glandular tissue. Cancer cells are named according to the organ in which they originate no matter where in the body we find such cells. Thus, if prostate cancer cells spread in the body to the bones, ...
Prostate cancer is comprised nearly always of adenocarcinomacells -- cells that arise from glandular tissue. Cancer cells are named according to the organ in which they originate no matter where in the body we find such cells. Thus, if prostate cancer cells spread in the body to the bones, ...
Black men are 2.2 times more likely to die from prostate cancer than non-Hispanic white men. Guidelines recommend that men make an informed decision about prostate cancer screening following a conversation with their clinician about risks and benefits. Despite known racial prostate cancer disparities,...
b Primary and metastatic cancer ROI outlined in black overlayed on H&E stained face sections. c GP5 tumor samples analyzed. L/R, left or right; Apex, prostate apex; CA, cancer in primary organ; LN, lymph node; Met, metastasis. See also Additional file 1; Fig. S1. Samples with ...
Disulfidptosis refers to cell death caused by the accumulation and bonding of disulfide in the cytoskeleton protein of SLC7A11-high level cells under glucose deprivation. However, the role of disulfidptosis-related genes (DRGs) in prostate cancer (PCa) c
Despite the publication of thousands of articles on PSA and pros- tate cancer screening, the value of early intervention remains unclear.2,3 The PCA3 gene, formerly known as DD3, was first identified in 1999.2 PCA3 is a non–protein-coding messenger RNA (mRNA) that is highly overexpressed ...
and Implications for Health Equity USPSTF Recommendation Statements Screening for Colorectal Cancer Screening for Hypertension Screening for Lung Cancer Screening for Prediabetes and Type 2 Diabetes In Children Screening for Prediabetes and Type 2 Diabetes In Adults Statins for Primary Prevention of Cardiova...
Age-related disparities in cancer screening: analysis of 2001 Behavioral Risk Factor Surveillance System data. Ann Fam Med 2004;2(5):481-7. 8. Smith RA, Cokkinides V, Eyre HJ. Cancer screen- ing in the United States, 2007: a review of current guidelines, practi...
Talk to your doctor about the risks and benefits ofprostate cancer screeningand having PSA testing if you are 40 years of age with a family history of prostate cancer (or age 50 if you do not have a family history), or are of African-American ancestry. The test results should be conside...
JAMA Original Investigation June 25, 2024 This prospective, multicenter cohort study evaluates the long-term outcomes of men diagnosed with favorable-risk prostate cancer managed with protocol-directed active surveillance, including regular biopsies and prostate-specific antigen screening, from 2008 to 2022...